Ascidian Therapeutics, Odyssey Therapeutics, Neumora
Odyssey Therapeutics Raises $168M in Series B Financing
Odyssey Therapeutics, a Boston, MA-based biotechnology company, raised $168M in Series B funding.
The round was led by General Catalyst, with participation from Fidelity Management & Research Company, T. Rowe Price Associates, GreatPoint Ventures, Catalio Capital Management, Walleye Capital, Alexandria Venture Investments, The Healthcare Innovation Investment Fund LLC, OrbiMed, SR One, Foresite Capital, Logos Capital, Woodline Partners LP, HBM Healthcare Investments, Colt Ventures and Creacion Ventures.
The company intends to use the funds to advance its portfolio of precision immunomodulators and oncology medicines in support of its mission of developing innovative medicines to treat serious human diseases.
Gary D. Glick, Ph.D., Founder and Chief Executive Officer, Odyssey Therapeutics is a biotechnology company focused on discovering, developing and commercializing immunomodulators and oncology medicines. Its immunology and oncology portfolio encompasses eight declared programs initially focused on small molecule and protein therapeutics. In addition, Odyssey is building a discovery engine that integrates artificial intelligence and machine learning for molecular design; a chemistry platform encompassing proprietary covalent libraries targeting multiple amino acids, molecular glues and natural products; and a functional genomics platform for novel target discovery.
Odyssey Therapeutics Raises $168M in Series B Financing
Odyssey Therapeutics, a Boston, MA-based biotechnology company, raised $168M in Series B funding
Neumora Therapeutics Raises $112M in Series B Financing
Neumora Therapeutics, a Watertown, MA-based clinical-stage biotechnology company, raised $112M in Series B funding.
The round was led by Abu Dhabi Growth Fund, Altitude Life Science Ventures, Amgen, ARCH Venture Partners, Exor Ventures, F-Prime Capital, Invus, Mubadala Capital, Newpath Partners, and Polaris Partners. Alaa Halawa, partner and head of U.S. Ventures at Mubadala Capital, joined Neumora’s board of directors.
The company intends to use the funds to support the advancement of a broad clinical and preclinical pipeline of novel precision medicine candidates for neuropsychiatric disorders and neurodegenerative diseases and the development of the its precision neuroscience platform.
Led by CEO Paul L. Berns, Neumora Therapeutics is a clinical-stage biotechnology company providing precision medicines for brain diseases through the integration of data science and neuroscience. Its data-driven precision neuroscience platform cuts through brain disease heterogeneity to match the right patient populations to targeted therapeutics.
Neumora Therapeutics Raises $112M in Series B Financing
Neumora Therapeutics, a Watertown, MA-based clinical-stage biotechnology company, raised $112M in Series B funding
Matchpoint Therapeutics Raises $100M in Series A and Seed Funding
Matchpoint Therapeutics, a Cambridge, MA-based biotechnology company, raised $100M in Series A and Seed funding.
The $70M Series A round was led by Sanofi Ventures with participation from Atlas Venture, Access Biotechnology, Vertex Ventures HC, Digitalis Ventures, and Alexandria Venture Investments. The $30M Seed round was co-led by Atlas Venture and Access Biotechnology.
The company intends to use the funds for further advancement of its proprietary platform and its discovery pipeline of novel covalent molecules, initially focused on immunology.
Founded by Drs. Gray, Chouchani, Dr. Jianwei Che, Andre Turenne (CEO) and Dr. Tinghu Zhang, Matchpoint is a biotechnology company harnessing covalency to discover covalent medicines for the treatment of immune diseases and other serious illnesses. Its proprietary Advanced Covalent Exploration (ACE) platform integrates chemoproteomics, machine learning and covalent chemistry library evolution.
Matchpoint Therapeutics Raises $100M in Series A and Seed Funding
Matchpoint Therapeutics, a Cambridge, MA-based biotechnology company, raised $100M in Series A and Seed funding.
Inversago Pharma Raises CAD$95M in Series C Financing
Inversago Pharma, a Montreal, Canada-based clinical stage biotech company, raised CA$95M in Series C funding.
The round was led by New Enterprise Associates, with participation from Forbion’s Growth, Amgen Ventures, Forbion Ventures, Fonds de solidarité FTQ, Genesys Capital, AmorChem, JDRF T1D Fund and adMare BioInnovations.
The company intends to use the funds to move Its program, INV-202, into a Phase 2 clinical trial in Diabetic Kidney Disease in Q4 2022.
Led by CEO François Ravenelle, Inversago Pharma is a biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on, peripherally-acting CB1 inverse agonists. The company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease, including Diabetic Nephropathy, Type 1 and Type 2 Diabetes, Non-Alcoholic Steatohepatitis, complications of obesity and hypertriglyceridemia, as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease, including Idiopathic Pulmonary Fibrosis and other conditions.
Inversago Pharma Raises CAD$95M in Series C Financing
Inversago Pharma, a Montreal, Canada-based clinical stage biotech company, raised CA$95M in Series C funding
Ascidian Therapeutics Raises $50M in Series A Funding
Ascidian Therapeutics, a Boston, MA-based biotechnology company, raised $50M in Series A funding.
The round was led by ATP.
The company intends to use the funds to expand its development efforts to extend the therapeutic potential of RNA medicines.
Led by CEO Romesh Subramanian, Ascidian Therapeutics is a biotech company whose technology enables therapeutic targeting of large genes and genes with high mutational variance while maintaining native gene expression patterns and levels. This approach is designed to provide the durability of gene therapy while reducing risks associated with DNA editing and manipulation. Ascidian’s platform deploys high-throughput molecular biology in tandem with computational biology. A single Ascidian RNA editor can replace multiple mutated exons simultaneously, without modifying DNA, thereby limiting the risk of off-target DNA edits and expression of transgenes in off-target cell types. Moreover, the technology does not require the introduction of exogenous enzymes, reducing the risk of immunogenicity.
Ascidian Therapeutics Raises $50M in Series A Funding
Ascidian Therapeutics, a Boston, MA-based biotechnology company, raised $50M in Series A funding
Custom Health Buys Health in Motion Network
Custom Health, a Mountain View, CA-based healthcare delivery company, acquired Health in Motion Network, an Ohio-based health information company.
The amount of the deal was not disclosed.
With the acquisition, Custom Health will expand its offering.
Led by CEO Ray Shealy, Health in Motion Network provides the Parawell software, which organizes patients’ important health information in a central and secure place. It enables patients and their care teams to manage and track all lab reports, medications, health records and telemetry data from monitoring devices.
Key executives joining the Custom Health management team from Health in Motion include:
Brian Slusser, Stakeholder Relations Ray Shealy, Platform Strategy Cathy Kuhn, Clinical Programs Led by CEO Rahul Chopra, Custom Health connects patients with their circle of care, help them to take meds as prescribed with digital health tools, then go beyond adherence to make sure those meds are working as intended.
Custom Health Buys Health in Motion Network
Custom Health, a Mountain View, CA-based healthcare delivery company, acquired Health in Motion Network, an Ohio-based health information company
Veranex Acquires Devicia and Clarvin
Veranex, a Raleigh, NC-basedmedical technology company, acquired Devicia, a Stockholm, Sweden-based provider of clinical expertise, also Clarvin, a Stockholm, Sweden-based provider of strategic guidance in regulatory affairs and quality assurance.
The amount of the deals was not disclosed.
With the acquisition, Veranex will further expand its European reach and build regulatory, clinical, and quality service segments. The group of companies adds three locations across Europe and the U.S. to Veranex’s global footprint.
Led by CEO Åsa Runnäs, Clarvin is the regulatory consultant for medical device and IVD manufacturers that guides and supports in every aspect of regulatory affairs and quality assurance processes. The team identifies customized regulatory intelligence solutions within rapidly emerging technologies and the evolving regulatory landscape.
Led by CEO Elisabeth Liljensten, Devicia is a consulting firm offering clinical expertise for medical devices, supporting clients throughout the life cycle of medical device and IVD.
Led by CEO David Dockhorn, Veranex is a tech-enabled service provider dedicated to the medical technology industry. Offering guidance from concept to commercialization and across the development continuum, the company enables accelerated speed to market, controlled development costs, development risk mitigation, and accelerated market viability assessment. At every stage, Veranex customers realize efficiencies in cost and time, while its comprehensive solutions unify and streamline the entire development process.
